Paul D. Smith
Queen Mary University of London(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Computational Drug Discovery Methods, PI3K/AKT/mTOR signaling in cancer, Melanoma and MAPK Pathways, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study(2012)657 cited
- → MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road(2015)604 cited
- → Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer(2012)437 cited
- → Challenges and Opportunities in Cancer Drug Resistance(2020)419 cited
- → Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation(2004)413 cited
- → AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models(2007)388 cited